TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Cost savings from LP formula strategy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: freedom from recurrent atrial tachyarrhythmia
Endpoint domain: Mortality/survival
Primary endpoint: better in asthma management test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pancreatic enhancement at 15 seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver and peripancreatic vessels enhancement at 25 seconds or later
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreasing blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 5-year cancer-specific survival (CSS)
Endpoint domain: Mortality/survival
Primary endpoint: Mild hypercalcemia prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum bactericidal activity titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incidence of immediate headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of delayed headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nighttime systolic ABP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VCAM‐1 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean changes in the area under the curve of the SMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rhinoconjunctivitis SMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of responders
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Headache recurrence within 48 hours post-ED discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean improvement in NRS points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient preference for medication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CK activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AST activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic pulse oximetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of first postoperative voiding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: overall hand condition improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: frequency of handwashing
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Pulmonary hypertension indicators (RPEP/RVET ratio, diameter ratio of pulmonary artery to aorta, acceleration time of pulmonary arterial blood flow)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: DNA methylation status of candidate genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced wrinkling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: better skin appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: general overall wellness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Development of secondary lymphoedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Cardiometabolic health measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: No radiographic progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rates of serious infections
Endpoint domain: Adverse events/effects
Primary endpoint: negative predictive values of stress SPECT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived medical need
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Doctors' perception of patient pressure
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: mean total area under the concentration-time curve of repaglinide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak plasma concentration of repaglinide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean incremental area under the concentration-time curve of serum insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in symptoms of depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in financial participation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Liver mass decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spleen mass decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative POMS value
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Urethrocutaneous fistula formation
Endpoint domain: Adverse events/effects
Primary endpoint: Total operative and enucleation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Postoperative pain medication usage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Recurrence of pancreatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: serum concentrations of clozapine or desmethylclozapine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma renin activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Chest tube clamping before removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: VO2max maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfaction derived from contributing to community health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: personal emotional and physical benefits derived from serving as a peer coach
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HMG requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cancellation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sIL‐2R levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sustain employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in interleukin 10 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in substance P levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: therapeutical visual outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: premature gastroduodenal phase III activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: duration of antral phase III
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: propagation velocity and wave frequency of gastroduodenal motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Talinolol oral bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-rater reliability of ankle joint dorsiflexion measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter-rater reliability of ankle joint dorsiflexion measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concurrent validity of ankle joint dorsiflexion measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alveolar dead space ratio (VD(alv)/VT(alv))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Intra-operative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Post-operative analgesics prescribed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time consumption of procedure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: clinical relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of infants fed with any human milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serotype-specific binding IgG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Functional antibodies levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of PCV7 and PCV13
Endpoint domain: Adverse events/effects
Primary endpoint: ACR20 improvement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR50 improvement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total nasal score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total nasal cavity volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality-Adjusted Life Years (QALY)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Venous thrombotic complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Objective tumor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cycle length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: maximum follicle size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: peak serum progesterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mortality at 1 year of follow-up
Endpoint domain: Mortality/survival
Primary endpoint: Rate of use of hospital services
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac death or myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: median probing depth reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alpha2-macroglobulin reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of CO2 embolisms
Endpoint domain: Adverse events/effects
Primary endpoint: Time to recovery to a TOF ratio of 0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of stunted children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: annual family expenditure on illness
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: perioperative hemoglobin loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: catheter removal time
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: pyelocaliceal perforation
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of acid reflux during TLESRs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of patients with normal sensory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean grip strength improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients reporting cold intolerance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: mean percentage change in 'off' UPDRS motor score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Permanence on the ventilator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global improvement score of post-treatment erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area of total microcrusts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transplantation-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Quality of Life (QoL) scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Social Functioning (SF)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Peak GH response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Patient-calculated MEWS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hyperinsulinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decreased insulin disposal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: restoration of enzyme
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical symptoms and signs improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episodes of hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nausea or vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: remission of contractions for 24 to 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time in range 3.9-7.8 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time in hyperglycemia (>10 mmol/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: EMG intensities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EMG burst duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duty cycle pedaling cadence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated blood loss during the third stage of labour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Active flexion at 6 weeks after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Water intake change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in prostate specific antigen by 50% or greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No signs of progression after 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3D displacement/remodeling vectors of gonion and pterygomaxillary fissure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight loss ≥10%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of deep venous thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean number of WBC in EPS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean NIH‐CPSI total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of lovastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total AUC of lovastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2,z of fluvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol consumption after stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative occurrence of TCR
Endpoint domain: Adverse events/effects
Primary endpoint: Disease exacerbation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Bowel-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: functional recovery at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma bilirubin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of biliary sludge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of GGT, ALP, and ALT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PaO2 after sternum closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Transaminases improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bilirubin improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum load to failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Accuracy of TearLab Osmolarity System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of measurements in normal range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: faster recovery from shock
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: jaundice levels (TBIL and DBIL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: liver enzyme levels (ALT and AST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-corrected cyclosporine area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration of cyclosporine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in auditory processing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in cortical responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: correlation dimension of EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pregnancy rates per initiated cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Pregnancy rates per embryo transfer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Rate of integration into the primary labour market
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Probability of respiratory symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: recurrent AHRF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ALT, AST, and TB levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver function outcomes
Primary endpoint: CD(4)(+) cells and NK cell activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: levels of TNF‐alpha, IL‐8, and sIL‐2R
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: composite of all-cause mortality, myocardial infarction, stroke, recurrent ischemia requiring hospitalization, and urgent revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients who returned to work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percentage of patients who tolerated a diet of normal consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of urinary tract infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Repeat visit rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Repeat antibiotic prescription rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean number of type 6 and 7 stools
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of patients with nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: iPTH serum concentration control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Median DNA yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of respiratory complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Overall CMV infections
Endpoint domain: Adverse events/effects
Primary endpoint: VFQ-25 composite score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Distance and near visual acuities improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in CRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3-5 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: hands-off time for airway management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of response to paroxetine treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peritoneal clearance of low molecular weight solutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes